Lumos Diagnostics (ASX: LDX) has signed an agreement with Regional Health Care Group (RHCG) for distribution of the FebriDx point-of-care test in Australia and New Zealand.
The agreement further expands the distribution of FebriDx through Henry Schein’s Medical business to include Australia and New Zealand. RHCG is a part of Henry Schein, Inc, the world’s largest provider of health care solutions to office-based dental and medical practitioners.
“At Henry Schein, our goal is to help health care professionals enhance efficiencies through practice care so they can focus on delivering quality patient care. We are therefore delighted to expand our distribution of FebriDx beyond Portugal, Spain, the Netherlands, the United Kingdom, and the United States to now include Australia and New Zealand,” said Mike Covey, Henry Schein Vice President – APAC Region and Managing Director, Australia.
FebriDx is a rapid POC test to differentiate a viral from bacterial acute respiratory infection. FebriDx delivers results after 10 minutes from fingerstick blood and can be used to help rapidly and accurately manage infectious patients in primary care, urgent care, emergency department, paediatric and other outpatient settings.
Regional Health Care Group will sell the FebriDx test throughout Australia and New Zealand with sales and marketing activities commencing immediately.
“It is great to see the increased interest in our FebriDx test from one of the world’s largest distributors of healthcare and medical products,” said Doug Ward, CEO of Lumos Diagnostics.
“Henry Schein has been a terrific and supportive partner for Lumos across Europe. With our recent US launch and the growing commercial interest in FebriDx, we are now preparing production of FebriDx to meet the anticipated growing demand for the product, to support our customers.
“ It is very exciting to have Henry Schein as part of this strategy with their expanded distribution coverage for FebriDx in the Australian and New Zealand markets.”
